A case of a hepatotoxicity occuring as a result of tobramycin adminstration has been published in the December issue of the Annals of Pharmacotherapy.
Liver enzymes rose when tobramycin therapy was initiated, markedly increased when the tobramycin dose was increased, then resolved upon discontinuation of therapy. Other medication-related causes were ruled out by temporal relationship or rechallenge (aztreonam). Use of the Naranjo probability scale indicated a possible relationship between hepatotoxicity and tobramycin therapy. Other adverse reaction scales specific for evaluation of drug-induced liver disease were also used. Both the Council for International Organizations of Medical Sciences and Maria and Victorino scales indicated a probable likelihood of tobramycin-induced hepatotoxicity.
Reference: The Annals of Pharmacotherapy 2007;41(12): 2061-2065.
http://www.theannals.com/cgi/content/abstract/41/12/2061
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment